Monitoring angiotensin receptor-neprilysin inhibitor usage and clinical outcomes in heart failure patients: Real-world evidence from a tertiary care center in Thailand
Science, Engineering and Health Studies · 09.07.2026 · 26050009
DOI: 10.69598/sehs.20.26050009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, Engineering and Health Studies, online erschienen am 09.07.2026. Verfasst von Phattranit Kamtuo und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
This retrospective study investigated the real-world usage patterns, effectiveness, and safety of the angiotensin receptor–neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) at a tertiary care center in Thailand. A total of 249 patients who initiated ARNI between January 1, 2018, and June 30, 2022, were included. The average age was 61.3 ± 11.1 years, and 69.1% were male. The mean BMI was 25.7 ± 13.4 kg/m², and the average body weight was 66.4 ± 13.8 kg. The baseline left ventricular ejection fraction (LVEF) was 28.4% ± 8.7%. Most patients (57.4%) were administered ARNI at a dose of 100 mg/day. The average follow-up was 18.5 months, and the maximum tolerable dose was 179.0 ± 98.7 mg/day, with 12.0% attaining the target dose. No deaths were recorded; however, 8.8% of the patients were hospitalized for heart failure. LVEF improved significantly at 6, 12, 18, 24, and 30 months, with 67.2% achieving LVEF ≥40%. Discontinuation of ARNI occurred in 20.9%, primarily due to hyperkalemia (9.3%), hypotension (6.0%), and a decrease in renal function (5.2%). These findings confirm ARNI’s effectiveness in improving cardiac function in Thai HFrEF patients while emphasizing the need for close monitoring to manage adverse effects and optimizing dosing strategies.
Zitieren
APA
Kamtuo, P., Jantharuechai, S., Wongvipaporn, C., & Uchaipichat, V. (2026). Monitoring angiotensin receptor-neprilysin inhibitor usage and clinical outcomes in heart failure patients: Real-world evidence from a tertiary care center in Thailand. Science, Engineering and Health Studies, 26050009. https://doi.org/10.69598/sehs.20.26050009
Vancouver
Kamtuo P, Jantharuechai S, Wongvipaporn C, Uchaipichat V. Monitoring angiotensin receptor-neprilysin inhibitor usage and clinical outcomes in heart failure patients: Real-world evidence from a tertiary care center in Thailand. Science, Engineering and Health Studies. 2026:26050009. doi:10.69598/sehs.20.26050009
BibTeX
@article{Kamtuo2026,
author = {Kamtuo, Phattranit and Jantharuechai, Siriporn and Wongvipaporn, Chaiyasith and Uchaipichat, Verawan},
title = {Monitoring angiotensin receptor-neprilysin inhibitor usage and clinical outcomes in heart failure patients: Real-world evidence from a tertiary care center in Thailand},
journal = {Science, Engineering and Health Studies},
year = {2026},
pages = {26050009},
doi = {10.69598/sehs.20.26050009}
}
EUVIMED